Paricalcitol altan 2 microgramos/ml solucion inyectable efg

Label: information for the user

Paricalcitol ALTAN5 micrograms/mL injectable solution EFG

Paricalcitol ALTAN2 micrograms/mL injectable solution EFG

Read this label carefully before starting to use the medication.

• Keep this label, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medication has been prescribed for you and should not be given to others, even if they have the same symptoms, as it may harm them.
• If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this label, inform your doctor or pharmacist.

The active ingredient ofParicalcitolALTANis paricalcitol. Paricalcitol is a synthetic (man-made) analog of vitamin D. In healthy individuals, the active form of vitamin D is naturally produced by the kidneys but when the kidney fails, the production of the active vitamin is reduced, which can cause low levels of calcium and high levels of parathyroid hormone in the blood. Paricalcitol is used to replace the active form of vitamin D produced naturally by the body.

ParicalcitolALTANis used for the prevention and treatment of secondary hyperparathyroidism (high levels of parathyroid hormone can cause bone problems) in patients undergoing hemodialysis as a result of renal failure.

If you have secondary hyperparathyroidism, you may notice that:

• You feel weak or tired.
• Your appetite decreases.
• You experience nausea or vomiting.
• You have pain in your bones or muscles.
• You need to urinate frequently.

Do not useParicalcitolALTAN:

• If you are allergic to paricalcitol or any of the other components of this medication (listed in section 6).
• If you have very high levels of calcium or vitamin D in your blood. Your doctor will monitor your blood levels and can tell you if these conditions apply to you.

Be especially careful withParicalcitolALTAN

• Before starting treatment, it is essential to limit the amount of phosphorus ingested in your diet. Examples of foods that contain high levels of phosphorus are: tea, soda, beer, cheese, milk, cream, fish, liver of chicken or beef, beans, peas, cereals, nuts, and whole foods.
• To control phosphorus levels, it may be necessary to use phosphate-binding agents that prevent the absorption of phosphorus from the diet.
• If you are taking phosphate-binding agents with calcium content, your doctor may need to adjust the dose.
• Your doctor will need to perform blood tests to monitor your treatment.

Use of other medications

Inform your doctor, nurse, or pharmacist if you are using or have recently used or may need to use any other medication.

Some medications may affect the action of ParicalcitolALTANor increase the risk of adverse effects. It is particularly important to inform your doctor if you are using any of the following medications:

• Para treat fungal infections such as candida or thrush (for example, Ketoconazol).
• To treat the heart or blood pressure (for example, digoxina and diuretics).
• That contain magnesium (for example, some types of medications for indigestion called antacids, such as magnesium trisilicato).
• That contain aluminum (for example, phosphate-binding agents, such as aluminum hydroxide).

Consult your doctor, nurse, or pharmacist before taking any medication.

Use ofParicalcitolALTANwith food and drinks

ParicalcitolALTANcan be administered before, after, or during meals. It is very important to follow the diet recommended by your doctor to obtain the maximum benefits of treatment and to prevent side effects. Do not take other vitamins/supplements (such as calcium, vitamin D) unless your doctor tells you to.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.

There is not enough data on the use of paricalcitol in pregnant women. The potential risk of its use in humans is unknown, so paricalcitol should not be administered unless it is clearly necessary.

It is unknown whether paricalcitol passes into breast milk. Inform your doctor if you are breastfeeding. Your doctor will decide if this treatment is necessary for you.

Driving and operating machinery

Paricalcitol may make you feel dizzy or confused; your ability to drive or operate machinery may be affected. Do not drive or operate machinery until you know how this medication affects you.

Important information about some of the components ofParicalcitolALTAN

ParicalcitolALTANcontains 11% v/v of ethanol (alcohol), which corresponds to 1.3 g per dose, equivalent to 2 ml of beer, or 1 ml of wine.

This medication is harmful to people with alcoholism.

The alcohol content should be taken into account in the case of pregnant women or breastfeeding women, children, and high-risk groups such as patients with liver disease or epilepsy.

The dose to be administered is calculated by your doctor. The paricalcitol dose varies for each patient. Your doctor will use laboratory test results to decide on the appropriate dose for you.

Once you have started treatment withParicalcitolALTAN, the dose may need to be adjusted, depending on how you respond to the treatment.

Administration form

ParicalcitolALTANwill be administered by your doctor intravenously (through a vein using a needle) while undergoing hemodialysis.

ParicalcitolALTANwill not be administered more than every other day.

Use ofParicalcitolALTANin children

There is no information on the use of paricalcitol in children under 5 years old, and experience is limited in children over 5 years old.

Your doctor will decide if this treatment is necessary.

If you take moreParicalcitol ALTANthan you should

Too muchParicalcitol ALTANmay cause high levels of calcium in the blood that may require treatment.

The symptoms that may appear quickly after receiving an overdose ofParicalcitol ALTANinclude:

• Weakness and/or drowsiness
• Headache.
• Sensation of nausea.
• Dry mouth, constipation.
• Muscle and bone pain.
• Strange taste in the mouth.

The symptoms that may appear after a long period of receiving too muchParicalcitol ALTANinclude:

• Loss of appetite
• Drowsiness
• Weight loss
• Irritation in the eyes
• Nasal discharge
• Itching skin
• Feeling hot and fever
• Loss of sexual desire
• Severe abdominal pain
• Kidney stones
• Your blood pressure may be affected and you may be aware of your own heartbeats (palpitations).

Paricalcitol ALTANcontains propylene glycol as a component. Isolated cases of toxic effects related to the administration of high doses of propylene glycol have been described, although they are not expected when administered to patients undergoing dialysis treatment because propylene glycol is removed from the blood during dialysis.

However, your doctor will monitor your blood levels and if you experience any of the mentioned symptoms, seek medical advice immediately.

In case of overdose or accidental ingestion, go immediately to a medical center or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

Like all medications,ParicalcitolALTANmay cause side effects, although not everyone will experience them.

Several allergic reactions have been reported with paricalcitol.Important: If you notice any of the following side effects, inform your doctor or nurse immediately:

• Shortness of breath
• Difficulty breathing and swallowing
• Wheezing
• Hives, skin itching or urticaria
• Swelling of face, lips, mouth, tongue or throat.

Inform your doctor or nurse if you notice any of the following side effects:

Frequent (may affect up to 1 in 10 people):

• Headache.
• Unusual taste in the mouth.
• Skin itching.
• Decreased parathyroid hormone levels.
• Increased levels of calcium (feeling sick, constipated or confused) and phosphorus in the blood (probably asymptomatic but may make bones susceptible to fracture).

Rare (may affect up to 1 in 100 people):

• Allergic reactions (such as difficulty breathing, wheezing, hives, itching or swelling of face and lips); blisters with itching.
• Blood infection, decreased red blood cell count (anemia – feeling weak, difficulty breathing, paleness); decreased white blood cell count (increased susceptibility to infections), lymph node inflammation in the neck, armpits and/or groin; prolonged bleeding time (blood will not clot quickly).
• Myocardial infarction, stroke, chest pain, irregular or rapid heartbeat, decreased blood pressure, increased blood pressure.
• Coma (deep state of unconsciousness during which a person cannot interact with their environment).
• Unusual fatigue, weakness, dizziness, syncope.
• Pain at the injection site.
• Pneumonia (lung infection), fluid in the lungs, asthma (wheezing, coughing, difficulty breathing).
• Throat irritation, cold, fever, feverish symptoms, pink eye (itching and crusts on eyelids), increased eye pressure, ear pain, nasal bleeding.
• Nervous tics; confusion, which in some cases is severe (delirium), agitation (feeling nervous, anxious), nervousness, personality disorders (not feeling like oneself).
• Tickling or numbness, decreased sensation, sleep problems, nocturnal sweating, muscle spasms in arms and legs, even during sleep.
• Dry mouth, thirst, nausea, difficulty swallowing, vomiting, loss of appetite, weight loss, heartburn, diarrhea and abdominal pain, constipation: rectal bleeding.
• Difficulty achieving an erection, breast cancer, vaginal infection.
• Chest pain, back pain, muscle or joint pain, feeling of heaviness caused by general or localized inflammation in ankles, feet and legs (edema); abnormal gait.
• Hair loss; excessive hair growth.
• Increased liver enzymes; increased parathyroid hormone levels, increased potassium levels in blood, decreased calcium levels in blood.

Unknown frequency:

• Swelling of face, lips, mouth, tongue and throat that may cause difficulty swallowing or breathing; skin itching (urticaria), gastric hemorrhage. Seek medical help immediately.

You may not identify these side effects unless your doctor has previously informed you.

If you consider any of the side effects you are experiencing to be severe or if you notice any side effect not mentioned in this prospectus, inform your doctor.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.

Paricalcitol ALTAN should be a clear and colorless solution. Do not use if the solution is discolored or contains particles.

This medication does not require special storage conditions.

Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.

Composition ofParicalcitolALTAN

• The active ingredient is paricalcitol.

Paricalcitol ALTAN5 micrograms/ml injectable solution

Each ml of solution contains 5 micrograms of paricalcitol. Each vial or ampoule of 1 ml contains 5 micrograms of paricalcitol. Each vial or ampoule of 2 ml contains 10 micrograms of paricalcitol.

ParicalcitolALTAN2 micrograms/ml injectable solution

Each ml of solution contains 2 micrograms of paricalcitol. Each vial or ampoule of 1 ml contains 2 micrograms of paricalcitol.

• The other components are: ethanol (alcohol), propylene glycol, and water for injectable preparations.

Appearance of the product and contents of the package

ParicalcitolALTANis a clear, colorless, and particle-free aqueous solution.

ParicalcitolALTAN5 micrograms/ml injectable solution

Available in:

Ampoules of 1ml containing 5 micrograms/ml

Ampoules of 2ml containing a total of 10 micrograms

or

Vials of 1ml containing 5 micrograms/ml

Vials of 2ml containing a total of 10 micrograms

ParicalcitolALTAN2 micrograms/ml injectable solution

Available in ampoules of 1ml containing 2 micrograms/ml

or

Available in vial of 1ml containing 2 micrograms/ml

Marketing Authorization Holder

Altan Pharmaceuticals S.A.

C/ Cólquide, Nº 6, Portal 2, 1ª Planta, Oficina F. Edificio Prisma, Las Rozas,

28230 Madrid

Spain

Manufacturer

RAFARM S.A.

Tesis Pousi-Hatzi, Agiou Louka

Peania, Attiki, 19002, P.O.BOX 37

This medicinal product is authorized in the Member States of the EU under the following names:

PT/H/451/01-02/DC

• PortugalREXTOL
• CzechREXTOL
• DenmarkParicalcitol Alternova
• SpainParicalcitolALTAN
• FinlandParicalcitol Alternova
• GreeceREXTOL

SlovakiaREXTOL

This leaflet was approved in:February 2017

The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)

http://www.aemps.gob.es

This information is intended solely for healthcare professionals:

ParicalcitolALTAN5 micrograms/ml injectable solution EFG

ParicalcitolALTAN2 micrograms/ml injectable solution EFG

Preparation for injectable solution

ParicalcitolALTAN2 and 5 micrograms/ml injectable solution is for single use. As with other parenteral medications, observe the solution for visible particles and color before administration.

Compatibility

Propylene glycol interacts with heparin and neutralizes its effects.ParicalcitolALTANinjectable solution contains propylene glycol as an excipient and should be administered through a different administration site from heparin.

This medication should not be mixed with other medications.

Storage and expiration

Parenteral products should be inspected before administration for visible particles and color. The solution is clear and colorless.

This medication does not require special storage conditions.

This medication has a shelf life of 2 years.

Dosage and administration

Paricalcitol ALTANinjectable solution is administered through the hemodialysis access.

Adults

1. The initial dose should be calculated based on the baseline levels of intact parathyroid hormone (PTH)

The initial dose of paricalcitol is based on the following formula:

Dose initial (micrograms) = basal level of PTH intact in pmol/l

8

Ó

= basal level of PTH intact in pg/ml

80

And administered as an intravenous (IV) bolus, with a maximum frequency of alternate days and at any time during dialysis.

The maximum safe dose administered in clinical studies was 40 micrograms.

1. Dose titration:

Accepted levels currently for the PTH range in patients with terminal renal failure undergoing dialysis is not more than 1.5 to 3 times the upper limit of normal non-uremic, 15.9 to 31.8 pmol/l (150-300 pg/mL) for intact PTH. To achieve the appropriate levels of physiological variables, individualized dose titration and monitoring are necessary.

If hypercalcemia or a corrected Ca x P product, elevated persistently, greater than5.2 mmol2/l2 (65 mg2/dl2), reduce or interrupt the dose until these parameters normalize. Then, restart paricalcitol administration at lower doses. It may be necessary to reduce the dose when PTH levels decrease in response to therapy.

The following table is suggested as an approximation for dose titration: